The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are: To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Preliminary Overall Response Rate (ORR)
Timeframe: Up to 16 cycles (each cycle is 21 days)
Progression-free survival (PFS)
Timeframe: From time of study enrollment until first documentation of progressive disease or death from any cause, assessed up to 3 years